Scholarlink

<p>The DNA damage response (DDR) and immune system serve as critical defence mechanisms, safeguarding genomic integrity and providing host protection, respectively. Emerging research reveals their interconnection in dictating the response to cancer immunotherapy. DDR-deficient tumours or those exposed to DDR inhibitors display genomic instability that generates two key immunogenic signals: neoantigens that activate tumour-specific T cells; and cytosolic DNA that stimulates the cyclic GMP-AMP synthase (cGAS)–stimulator of interferon genes (STING) pathway, triggering type I interferon production and immune cell recruitment. These synergistic effects drastically enhance responsiveness to immune checkpoint blockade. This Review examines the molecular mechanisms by which DDR defects potentiate immunotherapy, including recent advances in DDR-targeted combination strategies. We further analyse resistance mechanisms and discuss innovative approaches to overcome therapeutic limitations, offering a comprehensive perspective on exploiting DDR deficiencies for improved cancer treatment outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The DNA damage response and cancer immunotherapy

  • 期刊论文

  • 发表日期：

    2026年7月28日

查看全文
  • Sheng Hong,
  • Guo-Min Li

摘要

The DNA damage response (DDR) and immune system serve as critical defence mechanisms, safeguarding genomic integrity and providing host protection, respectively. Emerging research reveals their interconnection in dictating the response to cancer immunotherapy. DDR-deficient tumours or those exposed to DDR inhibitors display genomic instability that generates two key immunogenic signals: neoantigens that activate tumour-specific T cells; and cytosolic DNA that stimulates the cyclic GMP-AMP synthase (cGAS)–stimulator of interferon genes (STING) pathway, triggering type I interferon production and immune cell recruitment. These synergistic effects drastically enhance responsiveness to immune checkpoint blockade. This Review examines the molecular mechanisms by which DDR defects potentiate immunotherapy, including recent advances in DDR-targeted combination strategies. We further analyse resistance mechanisms and discuss innovative approaches to overcome therapeutic limitations, offering a comprehensive perspective on exploiting DDR deficiencies for improved cancer treatment outcomes.